Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion type Assertion NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_head.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion description "[Transgenic mice carrying human IL-6 cDNA fused with a murine major histocompatibility class-I promoter (H-2L(d)) were serially administered with anti-interleukin-6 receptor (IL-6R) monoclonal antibody (mAb), MR16-1, from the age of 4 weeks to estimate its efficacy on a variety of disorders developed in these mice, most of which are similar to the disorders associated with Castleman's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_provenance.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion evidence source_evidence_literature NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_provenance.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion SIO_000772 12633573 NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_provenance.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion wasDerivedFrom befree-20140225 NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_provenance.
- NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_assertion wasGeneratedBy ECO_0000203 NP806736.RAHI2k6xSOY6gfrP8VV9oWwB6RmzNHH-yuhG1td8ccTk4130_provenance.